Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC Masahiro TsuboiRoy S. HerbstYi-Long Wu Summary of Research Open access 11 March 2024 Pages: 131 - 134
Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia—A Podcast Elias J. JabbourMatthias Stelljes Commentary Open access 08 March 2024 Pages: 135 - 141
Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review Urszula ŻebrowskaWalentyna BalwierzAleksandra Wieczorek Systematic Review Open access 24 February 2024 Pages: 143 - 159
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review Patrick CrottyKarim KariMatt Vassar Systematic Review 11 March 2024 Pages: 161 - 173
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy Tomas BuchlerAlexandr Poprach Review Article Open access 03 February 2024 Pages: 175 - 180
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G Toshihiko MatsumotoYoshiyuki YamamotoKei Muro Original Research Article Open access 01 March 2024 Pages: 181 - 190
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK Rachael BattesonEmma HookPaul K. Paik Original Research Article Open access 16 March 2024 Pages: 191 - 201
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies Bi-Cheng WangBo-Hua KuangGuo-He Lin Original Research Article 30 January 2024 Pages: 203 - 212
Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data Alexander OlkusAurelie TomczakMichael T. Dill Original Research Article Open access 28 February 2024 Pages: 213 - 221
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab Margherita RiminiEleonora LoiAndrea Casadei-Gardini Original Research Article 12 February 2024 Pages: 223 - 235
Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia Dian JinHaoguang ChenZhen Cai Original Research Article Open access 11 March 2024 Pages: 237 - 249
Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study Gwan Hee HanHae-Rim KimHanbyoul Cho Original Research Article 28 February 2024 Pages: 251 - 262
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma Julia Maria ResslerErwin TomasichAnna Sophie Berghoff Original Research Article Open access 24 February 2024 Pages: 263 - 275
EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation Ruiying ZhaoJiaqi LiYuchen Han Original Research Article 28 February 2024 Pages: 277 - 288
Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer Connie Kang Adis Drug Evaluation 06 March 2024 Pages: 289 - 296
